Endocrine comorbidities including hypothyroidism and diabetes mellitus reported in 14 studies involving 1,659 participants reduced the efficacy of the first CRP, and participants needed a maximum of four to eight sessions, respectively, for complete recovery. The gene discussed is CRP; the disease is hypothyroidism.